Nicholas C DeVito, Colm Kelleher, Kyle C Strickland, James Abbruzzese, Carey Anders, Brent A Hanks, Jingquan Jia, Niharika B Mettu, Michael A Morse, Margot O'Neill, Hope Uronis, Yousuf Zafar, John H Strickler
Pancreatic adenocarcinoma commonly presents as metastatic disease and harbors a dire prognosis due to its aggressive behavior, propensity for resistance to therapies, and lack of targetable driver mutations. Additionally, despite advances in other cancers, immunotherapy has been ineffective in this disease thus far and treatment remains centered around cytotoxic chemotherapy. Here, we present a case of a patient with pancreatic adenocarcinoma harboring both high microsatellite instability (MSI-H) and HER2 amplification...
2021: AME Case Reports